ES2152412T3 - Preparacion farmaceuticamente estable de oxaliplatino. - Google Patents

Preparacion farmaceuticamente estable de oxaliplatino.

Info

Publication number
ES2152412T3
ES2152412T3 ES95925976T ES95925976T ES2152412T3 ES 2152412 T3 ES2152412 T3 ES 2152412T3 ES 95925976 T ES95925976 T ES 95925976T ES 95925976 T ES95925976 T ES 95925976T ES 2152412 T3 ES2152412 T3 ES 2152412T3
Authority
ES
Spain
Prior art keywords
pct
oxaliplatinum
oxaliplatino
pharmaceutically stable
stable preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95925976T
Other languages
English (en)
Inventor
Houssam Ibrahim
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Original Assignee
Debiopharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50845249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2152412(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm SA filed Critical Debiopharm SA
Application granted granted Critical
Publication of ES2152412T3 publication Critical patent/ES2152412T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA PREPARACION FARMACEUTICAMENTE ESTABLE DE OXALIPLATINO PARA ADMINISTRACION POR VIA PARENTERAL, QUE ESTA CONSTITUIDA POR UNA SOLUCION OXALIPLATINO EN AGUA EN UNA CONCENTRACION DE 1 A 5 MG/ML, CUYO PH ES DE 4,5 A 6. ESTA SOLUCION ACUOSA DE OXALIPLATINO SE PRESENTA VENTAJOSAMENTE EN FORMA DE UNA PREPARACION LISTA PARA USAR QUE ESTA CONTENIDA EN UN RECIPIENTE HERMETICAMENTE CERRADO.
ES95925976T 1994-08-08 1995-08-07 Preparacion farmaceuticamente estable de oxaliplatino. Expired - Lifetime ES2152412T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH246294 1994-08-08

Publications (1)

Publication Number Publication Date
ES2152412T3 true ES2152412T3 (es) 2001-02-01

Family

ID=50845249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95925976T Expired - Lifetime ES2152412T3 (es) 1994-08-08 1995-08-07 Preparacion farmaceuticamente estable de oxaliplatino.

Country Status (17)

Country Link
US (1) US5716988A (es)
EP (1) EP0774963B1 (es)
JP (1) JP3547755B2 (es)
KR (1) KR100365171B1 (es)
CN (1) CN1138541C (es)
AT (1) ATE197249T1 (es)
AU (2) AU2989695A (es)
BR (1) BR9508554A (es)
CA (1) CA2196922C (es)
CZ (1) CZ286714B6 (es)
DE (1) DE69519300T2 (es)
DK (1) DK0774963T3 (es)
ES (1) ES2152412T3 (es)
IL (1) IL114852A (es)
RU (1) RU2148400C1 (es)
UA (1) UA42779C2 (es)
WO (1) WO1996004904A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3547755B2 (ja) 1994-08-08 2004-07-28 デビオファーム・エス・アー オキサリプラティヌムの医薬的に安定な製剤
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6866857B1 (en) * 1998-10-14 2005-03-15 Debiopharm S.A. Oxalipatinum preparation packaging
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US7070796B1 (en) * 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
CA2382389C (fr) * 1999-08-30 2010-06-29 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
AU2002223013A1 (en) * 2000-12-12 2002-06-24 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
EP1368022B1 (fr) 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
CN102048723A (zh) 2003-08-28 2011-05-11 梅恩医药有限公司 含有酸的奥沙利铂制剂
ZA200604529B (en) * 2003-11-25 2007-12-27 Platco Technologies Proprietar Platinum (II) complexes, preparation and use
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
WO2005120480A1 (ja) * 2004-06-09 2005-12-22 Taiho Pharmaceutical Co., Ltd. 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法
EP1789427B1 (en) 2004-09-01 2009-05-20 Platco Technologies (Proprietary) Limited Preparation of platinum(ii) complexes
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
CN101389637A (zh) 2006-01-30 2009-03-18 普拉托技术（私有）公司 铂(ⅱ)配合物的制备
CN101442998B (zh) * 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
BRPI0806596A2 (pt) * 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
EP2152239A1 (en) * 2007-11-12 2010-02-17 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
AU2008352597B2 (en) 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja) 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
EP2481396A4 (en) 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2013202575B1 (en) * 2012-01-04 2013-05-16 Hospira, Inc. Dexmedetomidine premix formulation
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5314790B1 (ja) * 2012-07-09 2013-10-16 東和薬品株式会社 オキサリプラチン含有医薬組成物
EP2883542B1 (en) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
CN103690494B (zh) * 2013-11-29 2015-04-15 杭州华东医药集团新药研究院有限公司 一种低杂质含有奥沙利铂的组合物及其制备方法
CA2953350C (en) 2014-06-23 2019-11-26 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
CN104940151A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种抗癌药物奥沙利铂冻干粉针剂组合物
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
AU2017292650A1 (en) 2016-07-06 2018-12-13 H. Lundbeck A/S PDE9 inhibitors for treatment of peripheral diseases
SI3630772T1 (sl) 2017-05-26 2024-05-31 Cardurion Pharmaceuticals, Inc., Postopki izdelave in uporabe zaviralcev pde9
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
CN112996512B (zh) 2018-08-31 2025-01-03 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4657927A (en) * 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
NL8901433A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Carboplatinpreparaat.
JPH04185601A (ja) * 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
WO1994012193A1 (fr) * 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
JP3547755B2 (ja) 1994-08-08 2004-07-28 デビオファーム・エス・アー オキサリプラティヌムの医薬的に安定な製剤

Also Published As

Publication number Publication date
CA2196922A1 (fr) 1996-02-22
DE69519300T2 (de) 2001-05-31
KR970704434A (ko) 1997-09-06
RU2148400C1 (ru) 2000-05-10
IL114852A0 (en) 1995-12-08
CA2196922C (fr) 2004-06-01
UA42779C2 (uk) 2001-11-15
CN1154654A (zh) 1997-07-16
AU2989695A (en) 2000-03-07
ATE197249T1 (de) 2000-11-15
CZ286714B6 (en) 2000-06-14
KR100365171B1 (ko) 2003-02-19
AU731981B2 (en) 2001-04-12
DE69519300D1 (de) 2000-12-07
EP0774963B1 (fr) 2000-11-02
AU2252499A (en) 2000-03-23
CN1138541C (zh) 2004-02-18
IL114852A (en) 2000-02-29
WO1996004904A1 (fr) 1996-02-22
CZ37997A3 (en) 1997-06-11
US5716988A (en) 1998-02-10
EP0774963A1 (fr) 1997-05-28
BR9508554A (pt) 1997-11-25
JP3547755B2 (ja) 2004-07-28
DK0774963T3 (da) 2001-01-29
JPH10508289A (ja) 1998-08-18

Similar Documents

Publication Publication Date Title
BR9508554A (pt) Preparação farmaceuticamente estável de oxaliplatina
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
NO20023684L (no) Pediatrisk formulering
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
MXPA02008654A (es) Formulaciones de ranolazina de liberacion prolongada.
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
IL145187A0 (en) Echinocandin/carbohydrate complexes
DK1673074T3 (da) Flydende præparat, indeholdende tobramycin
AU1852597A (en) Multifunctional fat absorption and blood cholesterol reducing formulation containing chitosan and nicotinic acid
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR880007060A (ko) 제약 조성물
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
NZ507407A (en) Stable mitoxantrone solutions
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
AU2001289762A1 (en) Pharmaceutical extemporary compositions
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
Lin et al. Toxicity of a single oral dose of N-ethylphenylacetamide in rats
SE9700617D0 (sv) New composition
ES2125800A1 (es) Conjunto de infusion final.
ES2128966A1 (es) Composiciones farmaceuticas parenterales a base de calcitoninas sinteticas, de ph controlado, con bajo indice de dolor y buena estabilidad.
RU94036715A (ru) Лекарственное средство для лечения железодефицитных анемий у детей
MY104837A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
BG106890U (en) Liqiid medicamentous form

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 774963

Country of ref document: ES